Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) Research & Development (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Research & Development for 17 consecutive years, with $24.8 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 20.57% to $24.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $99.0 million through Dec 2025, down 14.22% year-over-year, with the annual reading at $99.0 million for FY2025, 14.22% down from the prior year.
  • Research & Development hit $24.8 million in Q4 2025 for Integra Lifesciences Holdings, up from $22.5 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $31.2 million in Q4 2024 to a low of $20.1 million in Q2 2021.
  • Historically, Research & Development has averaged $25.6 million across 5 years, with a median of $25.7 million in 2021.
  • Biggest five-year swings in Research & Development: soared 34.81% in 2021 and later fell 20.57% in 2025.
  • Year by year, Research & Development stood at $24.7 million in 2021, then rose by 8.32% to $26.8 million in 2022, then dropped by 9.33% to $24.3 million in 2023, then increased by 28.52% to $31.2 million in 2024, then dropped by 20.57% to $24.8 million in 2025.
  • Business Quant data shows Research & Development for IART at $24.8 million in Q4 2025, $22.5 million in Q3 2025, and $27.0 million in Q2 2025.